Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Ovarian Neoplasms × chiauranib × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Recurrence 1 Ovarian Neoplasms 1

Interventions

Paclitaxel 67 Carboplatin 56 Bevacizumab 28 liposomal doxorubicin 23 Topotecan 22 Gemcitabine 18 olaparib 16 Cisplatin 13 Doxorubicin 12 Drug Therapy 11 Taxes 10 niraparib 9 Docetaxel 6 Trabectedin 5 CP protocol 5 avelumab 4 atezolizumab 4 Immunoglobulin G 4 Ifosfamide 4 Hyperthermic Intraperitoneal Chemotherapy 4 Disulfides 4 Dexamethasone 4 Cyclophosphamide 4 Chemotherapy, Adjuvant 4 1-dodecylpyridoxal 4 trebananib 3 pembrolizumab 3 fluzoparib 3 dostarlimab 3 cediranib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04921527 2024-10-18

CHIPRO

Chipscreen Biosciences, Ltd.

Phase 3 Recruiting

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡